Company intelligence / Profile preview
MimiVax
Buffalo, New York, United Statesmimivax.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
MimiVax’s lead candidate, SurVaxM, has shown encouraging results in clinical trials for newly diagnosed glioblastoma. In a multi-center Phase IIa trial, median progression-free survival was reported at 11.4 months and median overall survival at nearly 26 months from first immunization—outcomes that compare favorably to historical controls. The ongoing fully enrolled Phase IIb SURVIVE trial continues after a positive interim futility analysis. SurVaxM has also received FDA Fast Track Designation and expanded Orphan Drug Designation for malignant gliomas.
- Therapeutic areas
- Oncology
- Modalities
- Peptide vaccines (immunotherapeutic vaccines)Targeted therapies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Collaborations with Roswell Park Comprehensive Cancer Centerpartnership-sponsored trials with pharmaceutical companies are sought but not specifically named
Beyond the preview
Go deeper on MimiVax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MimiVax.